Physician profile
Raul Marquez
NPI 1215914536
$2,494.04
in general payments reported to CMS, 2019-2025
28 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,028 · 2020: $183 · 2021: $16.24 · 2022: $172 · 2023: $418 · 2024: $148 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $569.22 | 2019-2024 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $447.62 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $159.10 | 2019 | |
| Genentech USA, INC. | $154.34 | 2019-2020 | |
| Insmed, INC. | $121.78 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $106.52 | 2019-2025 | |
| Abiomed | $101.95 | 2025 | |
| Philips North America LLC | $100.06 | 2019-2025 | Vest Therapy Und |
| Smith+Nephew, INC. | $71.14 | 2019 | |
| Gilead Sciences, INC. | $63.28 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $58.87 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $57.43 | 2025 | Purified Cortrophin Gel |
| Stryker Corporation | $52.88 | 2025 | Flowtriever |
| Mylan Specialty L.P. | $41.24 | 2023-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $40.99 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $40.50 | 2025 | Prolastin-C Liquid |
| Allergan, INC. | $38.78 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $34.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.55 | 2023 | Hyqvia |
| Vifor Pharma, INC. | $31.86 | 2025 | Zemaira |
| Pulmonx Corporation | $25.30 | 2020 | |
| Shire North American Group INC | $24.99 | 2019 | |
| Zoll Respicardia, INC. | $23.83 | 2024 | Remede System |
| Viiv Healthcare Company | $22.69 | 2019 | |
| Portola Pharmaceuticals, LLC | $22.49 | 2019 | |
| Pfizer INC. | $18.12 | 2023 | |
| United Therapeutics Corporation | $16.78 | 2025 | Tyvaso |
| Novartis Pharmaceuticals Corporation | $14.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Marquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.